Table 1 Characteristics of studies included for meta-analysis

Hodi [7]

RCT, phase III

Melanoma

676

Ipilimumab

3

3

Wilgenhof [14]

Prospective observational study

Melanoma

50

Ipilimumab

3

4

Delyon [15]

Prospective observational study

Melanoma

96

Ipilimumab

3

4

Margolin [16]

Open label, phase II

Melanoma

72

Ipilimumab

10

3

Hamid [17]

Randomized, double blind, phase II

Melanoma

82

Ipilimumab

3; 10

n/a

Danielli [18]

Single arm, phase II

Melanoma

13

Ipilimumab

10

3

Wolchok [19]

Randomised phase II, dose ranging study

Melanoma

217

Ipilimumab

0.3; 3; 10

3

O’Day [20]

Multicenter, single arm, phase II

Melanoma

155

Ipilimumab

10

3

Hersh [21]

RCT, phase II

Melanoma

74

Ipilimumab

3

2

Weber [22]

Randomized, double blind, phase II

Melanoma

115

Ipilimumab

10

3

Yang [23]

Randomized, double blind, phase II, dose ranging study

Renal cell

61

Ipilimumab

1; 3

n/a

Downey [24]

Multicenter, single arm, phase II

Melanoma

139

Ipilimumab

9

n/a

Ku [25]

Compassionate use trial

Melanoma

53

Ipilimumab

10

3

Di Giacomo [26]

Single arm, phase II

Melanoma

27

Ipilimumab

10

3

Royal [27]

Single arm, phase II

Pancreatic

27

Ipilimumab

3

3

Le DT [28]

Randomized, open label, phase IB

Pancreatic

30

Ipilimumab

10

3

Weber [29]

Phase I/II

Melanoma

88

Ipilimumab

n/a

n/a

Slovin [30]

Non randomized, open label, multicenter, phase I/II

Prostate

71

Ipilimumab

3; 5; 10

3

Calabro [31]

Open label, single arm, phase II

Mesothelioma

29

Tremelimumab

15

3

Chung [32]

Multicenter, single arm, phase II

Colorectal

47

Tremelimumab

15

3

Ralph [33]

Single arm, phase II

Gastric and esophageal

18

Tremelimumab

15

2

Ribas [34]

Phase I

Melanoma, renal cell, colon

39

Tremelimumab

10; 15

2